FDA Approves Abbott’s Next-Generation FreeStyle Libre 3 14-Day CGM

Abbott FreeStyle Libre 3 diabetes CGM sensor
The next-generation FreeStyle Libre 3 CGM sensor is the same size as two US pennies stacked together. [Image courtesy of Abbott]

Abbott (NYSE:ABT) announced today that it has received FDA clearance for its next-generation FreeStyle Libre 3 continuous glucose monitor.

FDA clearance for the latest version of the company’s FreeStyle Libre platform, designed as the world’s smallest and thinnest CGM sensor, covers use by people 4 years of age and older living with diabetes.

Get the full story on our sister site, Drug Delivery Business News.

Leave a Comment